Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06735248 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
A Phase 2 study of Multiple Sclerosis, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 17
- Study locations
NCT06735248: Recruiting Phase 2 study of Multiple Sclerosis, sponsored by ModernaTX.
NCT06735248 is a Phase 2 study of Multiple Sclerosis that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 180 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (69% lower). The trial reports 17 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06735248, a Phase 2 study of Multiple Sclerosis, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 17
- Study locations
Study Summary
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1195
Study Locations (17)
Other
- North Bristol NHS Trust - Southmead Hospital - Bristol
- Cardiff and Vale University Health Board - University Hospital Wales - Cardiff
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh - Edinburgh
- NHS Greater Glasgow & Clyde - Institute of Neurological Sciences - Glasgow
- Cambridge Clinical Research Centre - London
- East Kent Hospitals University NHS Foundation Trust - London
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Newcastle upon Tyne
- Sheffield Teaching Hospital NHS foundation Trust, Herries Road - Sheffield
Texas
- University of Texas Southwestern Medical Center - Dallas
- ANESC Research - El Paso
- Saturn Research Solutions - Plano
Missouri
- Sharlin Health & Neurology - Ozark
- Washington University School of Medicine Neurology Clinical Unit - St Louis
Massachusetts
- Boston Clinical Trials Inc - Internal Medicine - Boston
Michigan
- Quest Research Institute - Farmington Hills
Oklahoma
- Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence - Oklahoma City
Queensland
- University of the Sunshine Coast Clinical Trials - Birtinya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-04-16 |
| Est. Completion | 2029-01-08 |
| Phase | Phase 2 |
What NCT06735248 shows while recruiting
NCT06735248 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06735248 lists 17 locations in 7 states (Other, Texas, Missouri).
Frequently Asked Questions
What is clinical trial NCT06735248 about?
NCT06735248 is a clinical study titled "A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years". The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
What is the current status of trial NCT06735248?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-04-16. Estimated completion is 2029-01-08.
What conditions does trial NCT06735248 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT06735248?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1195 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06735248?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06735248 being conducted?
This trial has 17 study locations across Massachusetts, Michigan, Missouri, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06735248's enrollment target sits among peer trials
180 83rd of 315 higher than 233 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
-
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI